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率降低 69.5%，优于仅进行 VIA/VILI 筛查的 5 项方案（最低为 9.0%，最高为
69.2%，预防效果随筛查频率提高而显著提高）；常规接种并终生筛查 1次使宫
颈癌发病率降低 72.0%，常规接种并 3年筛查 1次使发病率降低达 89.4%。与不
进行干预相比，常规接种并终生筛查 2次的 ICER为 121292元/年，具有成本效
益。疫苗价格对方案的成本效益具有较大影响，当三支疫苗价格小于 600元，仅
常规接种或常规接种后在 16~39岁时补种的方案具有成本效益；当三支疫苗价格
































People's health is an important symbol of national prosperity, which should be put 
in the strategic position of priority development. We should adhere to prevention, 
advocate a healthy and civilized lifestyle and prevent major diseases. However, the 
per capita medical expense was still rising dramatically, which imposed heavy 
burdens to individuals, families, and society. As an interdisciplinary subject of 
economics and medicine, health economics focuses on solving the effective allocation 
of medical resources. For the prevention of serious diseases, balancing the current 
expense and the future output is important for programming the health policy. 
Currently, cervical cancer is the only cancer that could be prevented by vaccinations. 
Because the price of human papilloma virus (HPV) vaccine was expensive, 
unreasonable promotion of HPV vaccine would aggravate the health care burden 
doubtlessly. This study aims to evaluate the effect and cost-effectiveness of 
prevention strategies involving a prophylactic bivalent HPV vaccine. 
In the chapter two, this research systemically reviewed the published articles about 
health economics evaluation of HPV vaccination. This research found that the system 
dynamics model, which could depict the crowd barrier effection, provided the best 
prediction. Most studies demonstrated that HPV vaccine should be widely distribution 
in the evaluated-areas because of its cost-effectiveness. 
In the chapter three, a multiple health status dynamic model was developed to 
estimate the epidemiologic consequences and cost-effectiveness of prevention 
strategies. The model was a multi-state model, and each state was described from 
three attributes of gender, age structure and behavior heterogeneity. The least square 
method was used to calibrate the model 
In the chapter four, we evaluated the effect and cost-effectiveness of prevention 
strategies involving a prophylactic HPV vaccine. To explore the medical cost of 
cervical cancer and the influence factors, we collected cost data of patients with 
cervical cancer from a hospital of Xiamen. Secondly, we built 19 prevention strategies 
including visual inspection with acetic acid/lugol's iodine (VIA/VILI) and/or 3 does 
prophylactic bivalent HPV vaccine under the assumption that vaccine coverage and 
screening coverage were 70% and vaccination efficacy was 100%. The results 















incidence of cervical cancer by 69.5%, superior to 5 strategies including screening 
only. The range of effect was between 9.0% and 69.2%, and the effect of strategy 
increased significantly with the increase of screening frequency. Combination 
vaccination with screening at ages of 35 reduced the incidence of cervical cancer by 
72.0%, and the effect increased with the increase of screening frequency. 
Combination vaccination with screening every 3 years between 35 years and 64 years 
reduced the incidence by 89.4%. Compared with no-intervention, the incremental 
cost-effectiveness ratio (ICER) of combination vaccination with screening twice 
between 35 years and 64 years was 121292 CNY/life-year, which was cost-effective. 
The price of vaccine had a significant impact on the ICER of strategies, when the 
vaccine price was less than 600 CNY, 4 strategies including routine and/or catch-up 
vaccination were cost-effective; when the vaccine price was less than 1 200 CNY, 4 
strategies including routine and catch-up to 29 years vaccination and screening were 
cost-effective. 
In the chapter five, in order to improve the policy effect, the feasibility of 
prevention strategy needs to be analyzed. Therefore, we carried out the research on 
knowledge-attitude-behavior of prevention behavior of cervical cancer. we design a 
questionnaire, and sampled female students of all ages to learn about the support and 
influencing factors of their mother for cervical cancer prevention behavior. According 
to the survey data, HPV vaccine awareness rate and female vaccination rate were 
20.0% and 37.8% respectively. Even if the vaccine price was not considered, the rate 
of vaccination is only 57.9%. 69.5% had heard of cervical cancer screening, and 
40.4 % had undergone cervical cancer screening. Research suggests that actual 
vaccination rates and coverage of cervical cancer screening would be lower than 
expected. The health sector and pharmaceutical factory should take effort to promote 
cervical cancer etiology education and lower the price of the HPV vaccine. 
Therefore, the government should promote the use of HPV vaccine and cervical 
cancer screening as soon as possible. When formulating relevant policies, appropriate 
intervention plan should be adopted in combination with the procurement price of 
vaccine to seek the best cost benefit and maximum preventive effect. Given that the 
cost of the vaccine would affect the cost-effectiveness of the intervention programme, 
the government should actively negotiate with the pharmaceutical manufacturers to 















cervical cancer prevention policies, the awareness of HPV and cervical cancer should 
be raised in the population, so as to effectively improve the acceptance of cervical 
cancer screening and vaccination. 
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毒(Human Papilloma Virus, HPV)二价疫苗（Cervarix®）通过中国食品药品监督




务项目，免费为 1000万女性提供醋酸/复方碘染色肉眼观察（Visual Inspection 
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